BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31891627)

  • 21. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demographic trends and KRAS/BRAF
    Fu X; Huang Y; Fan X; Deng Y; Liu H; Zou H; Wu P; Chen Z; Huang J; Wang J; Lin H; Huang S; Tan X; Lan P; Wang L; Wang JP
    Int J Cancer; 2019 May; 144(9):2109-2117. PubMed ID: 30414169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reappraisal of the genetic heterogeneity of sessile serrated adenoma/polyp.
    Cho H; Hashimoto T; Yoshida H; Taniguchi H; Ogawa R; Mori T; Hiraoka N; Saito Y; Sekine S
    Histopathology; 2018 Oct; 73(4):672-680. PubMed ID: 29920740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exosomal miR-3131 derived from endothelial cells with KRAS mutation promotes EndMT by targeting PICK1 in brain arteriovenous malformations.
    He Q; Huo R; Wang J; Xu H; Zhao S; Zhang J; Sun Y; Jiao Y; Weng J; Zhao J; Cao Y
    CNS Neurosci Ther; 2023 May; 29(5):1312-1324. PubMed ID: 36718590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS and BRAF mutations in Serbian patients with colorectal cancer.
    Jakovljevic K; Malisic E; Cavic M; Krivokuca A; Dobricic J; Jankovic R
    J BUON; 2012; 17(3):575-80. PubMed ID: 23033302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma.
    Bagadi SB; Sanghvi M; Nair SB; Das BR
    Int J Biol Markers; 2012; 27(1):27-33. PubMed ID: 22427190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF and KRAS mutations in sporadic glomus tumors.
    Chakrapani A; Warrick A; Nelson D; Beadling C; Corless CL
    Am J Dermatopathol; 2012 Jul; 34(5):533-5. PubMed ID: 22317887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
    Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
    Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients.
    Li X; Yang T; Li CS; Song Y; Lou H; Guan D; Jin L
    Theranostics; 2018; 8(6):1678-1689. PubMed ID: 29556349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia.
    Juárez M; Egoavil C; Rodríguez-Soler M; Hernández-Illán E; Guarinos C; García-Martínez A; Alenda C; Giner-Calabuig M; Murcia O; Mangas C; Payá A; Aparicio JR; Ruiz FA; Martínez J; Casellas JA; Soto JL; Zapater P; Jover R
    PLoS One; 2017; 12(9):e0184937. PubMed ID: 28953955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Szumiłło J; Trojanowski T; Milanowski J
    Clin Exp Med; 2016 May; 16(2):169-76. PubMed ID: 25902737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
    BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective Endothelial Hyperactivation of Oncogenic KRAS Induces Brain Arteriovenous Malformations in Mice.
    Park ES; Kim S; Huang S; Yoo JY; Körbelin J; Lee TJ; Kaur B; Dash PK; Chen PR; Kim E
    Ann Neurol; 2021 May; 89(5):926-941. PubMed ID: 33675084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS mutation-induced EndMT of brain arteriovenous malformation is mediated through the TGF-β/BMP-SMAD4 pathway.
    Xu H; Huo R; Li H; Jiao Y; Weng J; Wang J; Yan Z; Zhang J; Zhao S; He Q; Sun Y; Wang S; Cao Y
    Stroke Vasc Neurol; 2023 Jun; 8(3):197-206. PubMed ID: 36418055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
    Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
    Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.